CC312 for autoimmune diseases that returned or didn't respond
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have one of these three conditions: lupus, myositis, or scleroderma, and it must be active despite previous treatments.
- You must have tried at least two standard therapies (like steroids or immune-suppressing drugs) for at least 3 months each without success.
- You must have stable doses of your current medications for at least 30 to 60 days before starting the study.
- You cannot have severe organ damage or other serious medical conditions that would make the study unsafe.
- Females who can have children must use effective birth control during and after the study; males must do the same.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called CC312 for people with moderate to severe lupus (SLE) that hasn't improved with standard treatments. The goal is to see if it is safe and can help control the disease.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
This trial tests a new injection (CM313) to see if it can help people with active lupus. It's for those whose lupus symptoms aren't fully controlled despite standard treatments.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This study tests a new experimental drug called SCTC21C in people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. The trial aims to see if this drug can help reduce lupus symptoms and inflammation when added to standard treatments.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.